Min MIn Qin

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C.

Part of Lepu Biopharma Co., Ltd., Shanghai Miracogen, Inc. is a Chinese company that engages in the development, clinical research, and industrialization of cancer targeted therapy drugs. The private company is based in Pudong, China. The company was founded in 2014 by Chao Hong Hu and Marry Hu. Marry Hu has been the CEO since 2014.

Zhejiang Teruisi Pharmaceutical Co., Ltd. is a private company based in Zhejiang, China that engages in the production of cancer medicine.